Nouscom raises USD 135 M

Nouscom is developing NOUS-209, a neoantigen-based immunotherapy designed to prevent cancers in carriers of Lynch syndrome. The Basel-based biotech has closed a Series D round of USD 135 million, co-led by M Ventures and Revelation Partners, to fund a global clinical trial towards registration.

Announced on
Round
Series C and later
Amount
USD 135 M
Location
Basel, canton of Basel-Stadt
Sector
Biotech & life sciences

Investors

Preparing a similar round?

The diagnostic shows you the instruments and investors that fit your stage.

Start the diagnostic